The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib-Reference-Cited by-同舟云学术

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

Published:2006 Issue:2 Volume:207 Page:420-427
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Normanno Nicola,Luca Antonella De,Maiello Monica R.,Campiglio Manuela,Napolitano Maria,Mancino Mario,Carotenuto Adele,Viglietto Giuseppe,Menard Sylvie

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference34 articles.

1. Overview of tyrosine kinase inhibitors in clinical breast cancer

2. Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer

3. Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer

4. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells;International Journal of Molecular Sciences;2024-04-29

2. The Multiple Functions of HB-EGF in Female Reproduction and Related Cancer: Molecular Mechanisms and Targeting Strategies;Reproductive Sciences;2024-02-29

3. Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy;Cancer Chemotherapy and Pharmacology;2024-01-04

4. Development of Gefitinib-Loaded Solid Lipid Nanoparticles for the Treatment of Breast Cancer: Physicochemical Evaluation, Stability, and Anticancer Activity in Breast Cancer (MCF-7) Cells;Pharmaceuticals;2023-11-02

5. Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors;Journal of Molecular Structure;2023-11